Patent cliff fuels Novartis’ $1.5bn swoop for London biotech
Key takeaway
Novartis acquires London biotech Myricx Bio for up to $1.5bn to offset patent cliff losses.
- Step 1 · The triggerNovartis acquires Myricx Bio for $1.5bn to address patent cliff.
- Step 2 · Knock-onDeal validates UK biotech innovation, attracting further Big Pharma M&A interest.
- Step 3 · Knock-onIncreased M&A activity boosts contract opportunities for UK CROs and CDMOs.
- Step 4 · Reaches youUK SMEs in drug development supply chain see potential revenue uplift from expanded outsourcing.
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: City A.M.
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for SMEsThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.